FFO
SUPN icon

Fortitude Family Office’s Supernus Pharmaceuticals SUPN Stock Holding History

Fortitude Family Office’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46K Buy
53
+45
+563% +$2.16K ﹤0.01% 1408
2026
Q1 		$414 Buy
8
+6
+300% +$306 ﹤0.01% 1791
2025
Q4 		$99 Sell
2
-1
-33% -$49 ﹤0.01% 1894
2025
Q3 		$143 Hold
3
– – ﹤0.01% 1939
2025
Q2 		$95 Buy
+3
New +$96 ﹤0.01% 2004

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Fortitude Family Office's SUPN Position: Q2 2026 in Review

Fortitude Family Office increased its Supernus Pharmaceuticals (SUPN) stake by 563% in Q2 2026, buying an estimated $2.16K and bringing the position to 53 shares worth $2.46K. The position accounts for ﹤0.01% of the portfolio, ranked #1408.

Fortitude Family Office first reported a position in SUPN in Q2 2025 and has held it in 5 quarters since. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Fortitude Family Office held 53 shares of Supernus Pharmaceuticals worth $2.46K as of Q2 2026.
  • Fortitude Family Office bought 45 Supernus Pharmaceuticals shares in Q2 2026, an estimated $2.16K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1408 holding.
  • Fortitude Family Office first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.